ArticleArchives of medical science : AMS2016
Molecular mechanisms of statin intolerance.
Article in Archives of medical science : AMS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 74 citations in OpenAlex.
- Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2017Trial
- Are statin side effects dependent on sex? A narrative review.Przeglad menopauzalny = Menopause review · 2025Review
- Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients.Chonnam medical journal · 2024Review
- Statins-From Fungi to Pharmacy.International journal of molecular sciences · 2023Review
- Possible link between statin and iron deficiency anemia: A South Korean nationwide population-based cohort study.Science advances · 2023Article
- Dysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin.Cell death & disease · 2023Article
- Rhabdomyolysis-induced acute kidney injury after administration of a red yeast rice supplement: A case report.World journal of clinical cases · 2023Article
- A mobile health application for patients eligible for statin therapy: app development and qualitative feedback on design and usability.BMC medical informatics and decision making · 2023Article
- Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System.Journal of clinical medicine · 2023Article
- Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies.Frontiers in pharmacology · 2023Review
- Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).Journal of cachexia, sarcopenia and muscle · 2022Review
- Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy.International journal of molecular sciences · 2021Review
- Article
- Improvement of Platelet Respiration by Cell-Permeable Succinate in Diabetic Patients Treated with Statins.Life (Basel, Switzerland) · 2021Article
- The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.European journal of applied physiology · 2020Review
- Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis.Annals of translational medicine · 2018Article
- Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018Review
- An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Personalized rosuvastatin therapy in problem patients with partial statin intolerance.Archives of medical sciences. Atherosclerotic diseases · 2018Article
- Protective effects of coenzyme QResearch in pharmaceutical sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins reduce cardiovascular morbidity and mortality in primary and secondary prevention. Despite their efficacy, many persons are unable to tolerate statins due to adverse events such as hepatotoxicity and myalgia/myopathy. In the case of most patients, it seems that mild-to-moderate abnormalities in liver and muscle enzymes are not serious adverse effects and do not outweigh the benefits of coronary heart disease risk reduction. The risk for mortality or permanent organ damage ascribed to statin use is very small and limited to cases of myopathy and rhabdomyolysis. Statin-induced muscle-related adverse events comprise a highly heterogeneous clinical disorder with numerous, complex etiologies and a variety of genetic backgrounds. Every patient who presents with statin-related side effects cannot undergo the type of exhaustive molecular characterization that would include all of these mechanisms. Frequently the only solution is to either discontinue statin therapy/reduce the dose or attempt intermittent dosing strategies at a low dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.